'Small-molecule cancer drug revenues will reach $27.3bn in 2015' predicts visiongain report
Visiongain predicts that small-molecule targeted cancer therapy revenues will reach $27.3bn worldwide in 2015. That overall market generated $20.3bn in 2010, according to Small-Molecule Targeted Cancer Therapies: World Market 2011-2021.
- (1888PressRelease) November 05, 2011 - Worldwide, more than 13 million patients were diagnosed with cancer in 2009; there may be 20 million new cases annually by 2025. Dr Syed Ahmed, a senior healthcare industry analyst at visiongain, said: "The number of cancer-related deaths is very significant. There is still an under-met need for therapeutic agents that not only prolong the survival of cancer patients but also greatly enhance their quality of life. Anti-cancer drugs - including small-molecule targeted cancer therapies - will remain a crucial part of the pharmaceutical market from 2011 to 2021."
Targeted cancer therapies are agents that block the growth and spread of cancer by interfering with molecules involved in tumour growth and progression. Most targeted therapies are either small-molecule drugs or monoclonal antibodies. Unlike antibody therapies, small-molecule targeted cancer drugs pass through cell membranes to reach targets inside the cell.
The report analyst added: "The market for small-molecule targeted cancer therapies is dominated by a number of blockbuster drugs led by Novartis' Glivec/Gleevec. Some of these products are due to lose patent protection this decade, offering opportunities for generic competitors. Nevertheless, a strong R&D pipeline for small-molecule cancer therapies makes this industry segment dynamic and promising for pharmaceutical companies."
Visiongain forecasts that the overall market for small-molecule targeted cancer therapies will grow steadily to 2021. Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate the small-molecule cancer drug market, the report concludes. This new study adds to visiongain's wide range of analytical reports on healthcare and other industries.
To view report sample pages please visit http://www.visiongain.com/Report/708/Small-Molecule-Targeted-Cancer-Therapies-World-Market-2011-2021
To request an exec summary please email Sara Peerun
Email: sara.peerun ( @ ) visiongainglobal dot com
Tel: +44 0207 336610
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun ( @ ) visiongainglobal dot com or call her on +44 (0) 207 336 6100